Gastric and esophageal cancer are characterized by the growth of cancerous (malignant) cells, which form a tumor within the lining of the stomach and esophagus. Several factors such as Barrett’s esophagus, excessive alcohol consumption, and smoking may causes gastric and/or esophageal cancer. Symptoms may include pain behind the breastbone, hoarseness, coughing, heartburn or indigestion, chest pain, weight loss, and difficulty in swallowing, among others. None of these signs and symptoms are seen in the early stages of cancer.
Request PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2438
Increase in number of clinical trials and increasing focus on the development of novel cancer drugs is expected to augment growth of the global gastric and esophageal cancer drugs market over the forecast period. For instance, in April 2016, Centre hospitalier régional universitaire de Besançon (Centre Hospitalier Universitaire de Besançon) initiated Phase I and II clinical trial for Carboplatin to determine the maximum tolerated dose (MTD) and recommended doses for phase II (RP2D) by considering the treatment scheme of Dutch study for radiotherapy and chemotherapy. The trial is conducted in elderly patients with esophagus cancer.
Moreover, in February 2017, Jiangsu HengRui Medicine Co., Ltd. and Henan Cancer Hospital initiated exploratory clinical trial (Phase II) to evaluate the effectiveness of Apatinib, used to treat advanced esophagus cancer.
High cost of cancer treatment is expected to hinder growth of the global gastric and esophageal cancer drugs market during the forecast period. For instance, according to the report published in 2013 in Healthday, cancer patients paid around US$ 207,000 per year for their treatment and medicines, while in 1995, the cost of treatment was US$ 54,100 per year.
North America is expected to witness robust growth in the global gastric and esophageal cancer drugs market due to the increasing prevalence of esophageal cancer, especially in the U.S. For instance, according to the American Cancer Society, by 2019, there will be an estimated 17,650 new cases of esophageal cancer diagnosed in the United States.
Major players active in the global gastric and esophageal cancer drugs market are Eli Lilly and Company, Amgen, F. Hoffmann-La Roche, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Bristol-Myers Squibb, Novartis AG, Gilead Sciences, Johnson & Johnson, Merck & Co. and Bristol-Myers Squibb Company, among others.
In January 2019, GlaxoSmithKline acquired TESARO, Inc. to strengthen its pharmaceutical business and to accelerate GSK’s pipeline and commercial capability in oncology.
In September 2018, Boehringer Ingelheim announced the acquisition of ViraTherapeutics, a biopharmaceutical company to strengthen its commitment to research & development for viral-based immuno-oncology treatment.
Get PDF Sample Copy of Report (Including Full TOC, List of Tables & Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-sample/2438
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Gastric and Esophageal Cancer Drugs Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Gastric and Esophageal Cancer Drugs Industry Impact
Chapter 2 Global Gastric and Esophageal Cancer Drugs Competition by Types, Applications, and Top Regions and Countries
2.1 Global Gastric and Esophageal Cancer Drugs (Volume and Value) by Type
2.3 Global Gastric and Esophageal Cancer Drugs (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Gastric and Esophageal Cancer Drugs Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Gastric and Esophageal Cancer Drugs Market Analysis
Chapter 6 East Asia Gastric and Esophageal Cancer Drugs Market Analysis
Chapter 7 Europe Gastric and Esophageal Cancer Drugs Market Analysis
Chapter 8 South Asia Gastric and Esophageal Cancer Drugs Market Analysis
Chapter 9 Southeast Asia Gastric and Esophageal Cancer Drugs Market Analysis
Chapter 10 Middle East Gastric and Esophageal Cancer Drugs Market Analysis
Chapter 11 Africa Gastric and Esophageal Cancer Drugs Market Analysis
Chapter 12 Oceania Gastric and Esophageal Cancer Drugs Market Analysis
Chapter 13 South America Gastric and Esophageal Cancer Drugs Market Analysis
Chapter 14 Company Profiles and Key Figures in Gastric and Esophageal Cancer Drugs Business
Chapter 15 Global Gastric and Esophageal Cancer Drugs Market Forecast (2022-2028)
Chapter 16 Conclusions
Buy This Report with Flat USD 2000 Off @ https://www.coherentmarketinsights.com/promo/buynow/2438
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027